Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01443728 · ClinicalTrials.gov registry record · Phase 2
Vitamin D for Sickle-cell Respiratory Complications
A Phase 2 study of Asthma and Sickle Cell Disease, sponsored by Gary M Brittenham, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT01443728 is a Phase 2 study of Asthma and Sickle Cell Disease that has completed, run by Gary M Brittenham, MD. The registered enrollment target is 70 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01443728, a Phase 2 study of Asthma and Sickle Cell Disease, has completed, sponsored by Gary M Brittenham, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to answer the question whether oral vitamin D supplementation can decrease lung complications in children and adolescents with sickle cell disease. Lung complications are the leading causes of morbidity and of death in sickle cell disease. Infections and increased inflammation play important roles in the development of the lung problems in sickle cell disease. Emerging evidence shows that vitamin D helps the immune system to fight infection and to control inflammation and could potentially help prevent respiratory complications in patients with sickle cell disease. The investigators hypothesize that oral vitamin D3, 100,000 IU (2.5 mg), given once a month to a group of children and adolescents with sickle cell disease, will reduce the rate of respiratory events (infection, asthma exacerbation and acute chest syndrome) compared to the rate in a group given standard dose oral vitamin D3, 12,000 IU (0.3 mg) given once a month. Funding Source - U.S. Food \& Drug Administration, Office of Orphan Products Development
Conditions Studied
Interventions
- DRUG Experimental: Vitamin D3 100,000 IU
- DRUG Active Comparator: Vitamin D3 12,000 IU
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2011-12-13 |
| Est. Completion | 2015-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01443728
The ClinicalTrials.gov registry entry for NCT01443728 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (96% lower). The listed sponsor is Gary M Brittenham, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Experimental: Vitamin D3 100,000 IU is the first listed.
NCT01443728 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01443728 about?
NCT01443728 is a clinical study titled "Vitamin D for Sickle-cell Respiratory Complications". This study aims to answer the question whether oral vitamin D supplementation can decrease lung complications in children and adolescents with sickle cell disease. Lung complications are the leading causes of morbidity and of death in sickle cell disease. Infections and increased inflammation play i...
What is the current status of trial NCT01443728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2011-12-13. Estimated completion is 2015-02-15.
What conditions does trial NCT01443728 study?
This clinical trial studies the following conditions: Asthma, Sickle Cell Disease, Vitamin D Deficiency, Acute Chest Syndrome, Respiratory Infections.
What interventions are being tested in trial NCT01443728?
The interventions under investigation include: Experimental: Vitamin D3 100,000 IU (DRUG), Active Comparator: Vitamin D3 12,000 IU (DRUG).
Who is sponsoring clinical trial NCT01443728?
This trial is sponsored by Gary M Brittenham, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01443728 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.